Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Announces Earnings Results

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) issued its earnings results on Wednesday. The company reported $0.18 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.18, reports. Bayer Aktiengesellschaft had a positive return on equity of 16.46% and a negative net margin of 0.68%.The company had revenue of $13.24 billion for the quarter, compared to the consensus estimate of $13.08 billion. Bayer Aktiengesellschaft updated its FY 2026 guidance to 1.251-1.400 EPS.

Bayer Aktiengesellschaft Trading Up 0.3%

Shares of OTCMKTS:BAYRY traded up $0.03 during trading on Thursday, hitting $11.04. The company had a trading volume of 159,693 shares, compared to its average volume of 1,314,203. The stock has a market cap of $43.39 billion, a price-to-earnings ratio of -122.65, a price-to-earnings-growth ratio of 4.34 and a beta of 0.69. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.14 and a quick ratio of 0.71. The company has a fifty day simple moving average of $12.43 and a two-hundred day simple moving average of $9.87. Bayer Aktiengesellschaft has a one year low of $5.30 and a one year high of $14.85.

Key Stories Impacting Bayer Aktiengesellschaft

Here are the key news stories impacting Bayer Aktiengesellschaft this week:

• Positive Sentiment: Q4 results broadly in line and guidance steady — Bayer reported Q4 EPS of $0.18 (meeting estimates) and revenue roughly in line/above expectations ($13.24B vs. $13.08B est.); the company set FY‑2026 EPS guidance of 1.251–1.400, which implies stable earnings growth and reduces near‑term forecast uncertainty. MarketBeat: BAYRY profile & earnings note
• Positive Sentiment: Initial court sign-off on Roundup settlement reduces long-running legal uncertainty — a Missouri judge gave initial approval to a proposed $7.25B settlement to resolve thousands of Roundup claims, which can shorten legal tail‑risk even though cash/charge implications remain sizable. Reuters: Roundup settlement initial OK
• Neutral Sentiment: Earnings call tone: “solid execution” but legal overhang persists — management emphasized operational execution but warned that litigation remains a material headline risk, keeping investor focus split between fundamentals and legal outcomes. TipRanks: Earnings call summary
• Neutral Sentiment: Full transcript and analyst color available — the call transcript and analyst notes provide details on product trends and guidance assumptions for investors doing deeper due diligence. Seeking Alpha: Q4 2025 earnings transcript
• Negative Sentiment: Large litigation-related charge widened the net loss — Bayer reported a steeper net loss including a ~€3.55B hit tied to litigation, which pressures near‑term profitability and cash flow metrics. WSJ: Net loss widens on litigation charges
• Negative Sentiment: Pharma sales headwinds — weaker sales of Xarelto and Eylea weighed on revenue growth in the quarter, signaling product‑level pressure even as overall results were roughly in line. Zacks: Xarelto, Eylea sales pressure

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. JPMorgan Chase & Co. raised Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Barclays raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. DZ Bank downgraded Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a research note on Wednesday, February 18th. Finally, Zacks Research cut Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a report on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.